Eylea

Drug name: Aflibercept intraocular injection solution

Trade name: Eylea

English name: aflibercept

Indications

EYLEA is suitable for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD).

Significant dosage

The 40 mg/mL solution is available in single-use vials for intravitreal injection.

Usage and dosage

(1) Only for ophthalmic intravitreal injection.

(2) The recommended dose of EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 3 months, followed by 2 mg (0.05 mL) administered by intravitreal injection every 8 weeks (2 months).

(3) Although EYLEA may be administered as frequently as 2 mg every 4 weeks (monthly), EYLEA did not show increased efficacy when administered every 4 weeks compared with every 8 weeks.

Common Side Effects

The most common adverse reactions (≥5%) reported in patients receiving EYLEA are conjunctival hemorrhage, ocular pain, cataracts, vitreous detachment, vitreous floaters, and increased intraocular pressure.

Precautions

(1) Endophthalmitis and retinal detachment may occur after intravitreal injection. Patients should be instructed to report without delay any suggestive endophthalmitis or retinal detachment and should be managed appropriately.

(2) An increase in intraocular pressure has been seen within 60 minutes of intravitreal injection.